Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors

Trial Profile

A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2019

At a glance

  • Drugs CGM 097 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Mar 2019 Planned End Date changed from 9 Jan 2019 to 19 Dec 2019.
    • 28 Mar 2019 Planned primary completion date changed from 9 Jan 2019 to 18 Dec 2019.
    • 05 Jun 2018 Planned End Date changed from 17 Jun 2018 to 9 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top